Every 8-K that Viatris Inc. (VTRS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow VTRS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VTRS filings page.
Viatris Inc. reported second-quarter 2026 total revenues of $3.76 billion, up 5% year over year, and a U.S. GAAP net loss of $118.8 million. The loss was driven largely by a $177.8 million non‑cash charge tied to the planned sale of Tyrvaya product rights.
On a non‑GAAP basis, adjusted net earnings were $808.5 million, adjusted EBITDA was $1.19 billion, and adjusted EPS was $0.69, each rising about 10% or more from the prior‑year quarter. Free cash flow was $329.0 million, nearly doubling from a year earlier, and the gross leverage ratio improved to 2.9x.
Viatris raised the midpoints of its 2026 guidance, now targeting total revenues of about $14.75 billion, adjusted EBITDA of $4.40 billion, adjusted EPS of $2.52, and free cash flow excluding transaction‑related and restructuring‑related costs of $2.20 billion. The company advanced its pipeline with FDA approval of Gwyn Lo and a generic ferric carboxymaltose injection, agreed to sell global Tyrvaya rights for up to $100 million, completed monetization of its Biocon stake, and expects Nashik manufacturing disruptions to reduce second‑half 2026 revenues by $100 million to $150 million while continuing to return capital, including $550 million to shareholders and repayment of $900 million of debt.
Viatris Inc. has entered into an amended and restated term loan credit agreement providing a senior unsecured term loan facility of ¥40,000,000,000. The company plans to use the funds for general corporate purposes, including repaying its prior ¥40,000,000,000 unsecured term loan facility dated July 1, 2021.
The new Term Loan Credit Facility initially bears interest at the TIBO Rate plus 1.10% per year, with the margin adjustable based on Viatris’ long-term unsecured debt ratings. It includes customary covenants and a financial covenant requiring a leverage ratio no greater than 3.75 to 1.00 at each quarter-end after closing.
The facility is guaranteed by certain subsidiaries and matures three years from the closing date, with amounts voluntarily prepayable at any time without penalty other than customary breakage costs.
Viatris Inc. completed a public offering of €650,000,000 aggregate principal amount of 4.250% senior unsecured notes due June 17, 2033, guaranteed by Mylan Inc., Mylan II B.V. and Utah Acquisition Sub Inc. The notes were issued under an existing shelf registration.
The company intends to use the net proceeds mainly to repay amounts borrowed under its revolving credit facility that funded the repayment at maturity of $1.675 billion of 3.950% senior notes due 2026, with any remainder to replenish cash for general corporate purposes. The notes pay 4.250% interest annually starting June 17, 2027, include optional redemption before and after an April 17, 2033 par call date, and require a 101% repurchase offer upon certain change of control events.
Viatris Inc. entered into an underwriting agreement to issue and sell €650,000,000 principal amount of 4.250% Senior Notes due 2033. The notes will be offered under an effective shelf registration on Form S-3, using a prospectus dated May 8, 2025 and a prospectus supplement dated June 12, 2026.
The offering is expected to close on June 17, 2026, subject to customary closing conditions. BNP Paribas, Citigroup Global Markets Limited and Goldman Sachs & Co. LLC are acting as representatives of the underwriters. The agreement includes customary representations, warranties and termination provisions.
Viatris Inc. reported the results of its 2026 annual shareholder meeting, where three proposals were considered. Shareholders elected thirteen director nominees to serve until the 2027 annual meeting, with each nominee receiving a clear majority of votes cast in favor.
Shareholders also approved, on a non-binding advisory basis, the 2025 compensation of the company’s named executive officers, with 846,370,157 votes for, 26,920,688 against, and 2,266,069 abstentions, plus 122,461,640 broker non-votes. They further ratified the selection of Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2026, with 969,259,214 votes for, 27,657,863 against, and 1,101,477 abstentions.
Viatris Inc. reported stronger first-quarter 2026 results, with clear growth on a non-GAAP basis and reaffirmed full-year guidance. Total revenues were $3.5 billion, up 8% reported and 3% operationally versus first-quarter 2025, driven largely by Greater China. Adjusted EBITDA reached $1.0 billion, up 14%, while adjusted EPS rose to $0.59, up 18%. U.S. GAAP net earnings were $176 million, compared with a $3.0 billion loss a year earlier that included a large goodwill impairment. Operating cash flow was $388 million and free cash flow $348 million, both below last year, though free cash flow excluding transaction- and restructuring-related costs was $459 million. Management reaffirmed 2026 guidance, including total revenues of $14.45–$14.95 billion, adjusted EBITDA of $4.15–$4.45 billion, adjusted EPS of $2.33–$2.47, and free cash flow excluding transaction- and restructuring-related costs of $1.95–$2.35 billion.
Viatris Inc. announced a planned Chief Financial Officer transition. Theodora “Doretta” Mistras will step down as CFO effective May 8, 2026, remaining employed until May 22, 2026 to support the handover, and her departure is stated as unrelated to any disagreements over accounting, financial reporting, internal controls or operations.
The Board appointed Paul Campbell, the current Chief Accounting Officer and Corporate Controller, as interim CFO effective May 8, 2026 while it searches for a permanent successor. Mistras will receive a pro rata 2026 bonus based on actual performance (capped at target) but no severance or equity vesting, and must sign a release and comply with restrictive covenants. Viatris also reiterated that it will release first‑quarter 2026 results on May 7, 2026 and hold a conference call at 8:30 a.m. ET.
Viatris Inc. reported 2025 total revenues of $14.3B, down 3%, and a U.S. GAAP net loss of $3.5B driven largely by a $2.9B goodwill impairment. Adjusted EBITDA was $4.16B, down 11%, while free cash flow was $1.94B.
The company completed an enterprise-wide strategic review and plans a global workforce reduction of up to 10%, expecting $700M–$850M in pre-tax restructuring charges and potential annual savings of $600M–$700M. For 2026, Viatris guides to revenues of $14.45B–$14.95B, adjusted EBITDA of $4.15B–$4.45B, and adjusted EPS of $2.33–$2.47, and estimates free cash flow excluding transaction- and restructuring-related costs of $1.95B–$2.35B.
Viatris Inc. reported a leadership change in its top legal role. Chief Legal Officer Brian Roman will step down from that position effective February 9, 2026 and remain with the company until April 1, 2026 to support the transition.
In connection with his departure, he will be eligible for separation payments equal to his base salary plus target bonus and a pro rata 2026 bonus, consistent with benefits for similar executives, and would sign a customary release of claims. Viatris also announced that Matthew Maletta, who previously served as Executive Vice President, Chief Legal Officer and Secretary of Endo, Inc. from 2015 to 2025, will join as Chief Legal Officer on February 9, 2026.
Viatris Inc. furnished an update on its latest results. The company issued a press release reporting financial results for the period ended September 30, 2025, and furnished it under Item 2.02 of an 8‑K. The information is provided as furnished, not filed, and is included as Exhibit 99.1.
The company also announced a conference call and live webcast today at 8:30 a.m. ET to review third-quarter 2025 results. Additional exhibit materials include the cover page Inline XBRL tags (Exhibit 104).
Viatris Inc. amended and restated its bylaws effective October 24, 2025, updating proxy access timing rules when the annual meeting date shifts. The company set its 2026 annual meeting for May 15, 2026.
Shareholder deadlines: Rule 14a-8 proposals are due by November 24, 2025. Proxy access nominations (up to the greater of two nominees or 20% of the Board) must be received between December 16, 2025 and January 15, 2026. Advance notice for other director nominations or business must be delivered between January 15, 2026 and February 14, 2026. Universal proxy notices under Rule 14a-19 are due by March 16, 2026.